OHR-1601 – Sponsored by Ohr Pharmaceuticals, Inc.Completed Study | Duration: 24 months
OHR-1601 was a multi-center, randomized, and double-masked Phase III clinical trial for the treatment of wet Age-Related Macular Degeneration (wet AMD). It compared the efficacy of topical Squalamine lactate (in the form of an eye drop) in combination with intravitreal Lucentis® vs. intravitreal Lucentis® alone. Squalamine lactate targets VEGF and other protein growth factors that are key in the formation of new blood vessels. This trial was for patients with newly diagnosed wet AMD who had received no prior anti-VEGF treatment. Participants were treated and followed for 24 months.